Xcorporeal, Inc. (XCRP) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Xcorporeal, Inc. (XCRP) trades at $0.0001 with AI Score 52/100 (Grade B). Xcorporeal, Inc. is currently in the process of liquidation and dissolution, having transferred its assets to a liquidating trust. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for XCRP: XCRP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates XCRP against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
XCRP: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Xcorporeal, Inc. (XCRP) Healthcare & Pipeline Overview
Xcorporeal, Inc., currently undergoing liquidation and dissolution, formerly operated as a medical device company. It focused on developing extra-corporeal platform technology for organ replacement. The company transferred its assets to a liquidating trust in 2010 and is no longer actively developing medical devices.
What Is the Investment Thesis for XCRP?
Xcorporeal, Inc. presents a unique situation for investors, as the company is currently undergoing liquidation. The primary value driver is the assets held within the Xcorporeal, Inc. Liquidating Trust and the potential for distribution to shareholders after all liabilities are settled. Investors should carefully examine the trust documents and financial reports, if available, to assess the potential recovery value. Given the company's state of liquidation since 2010, there are no growth catalysts related to its former medical device operations. The investment thesis hinges entirely on the efficient and timely liquidation of assets and the distribution of proceeds to shareholders. The high beta of 58.42 reflects the speculative nature of the stock.
Based on FMP financials and quantitative analysis
XCRP Key Highlights
Xcorporeal, Inc. is currently in liquidation, with all assets transferred to the Xcorporeal, Inc. Liquidating Trust.
- The company's market capitalization is $0.00B, reflecting its state of liquidation.
- Free cash flow is negative ($-0.00B), indicative of the company's lack of ongoing operations.
- The company does not offer a dividend, as it is in liquidation.
- The beta of 58.42 indicates extremely high volatility and speculative interest.
Who Are XCRP's Competitors?
XCRP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are XCRP's Key Strengths?
Previously held proprietary extra-corporeal platform technology.
- Experienced management team in medical device development (prior to liquidation).
- Established Xcorporeal, Inc. Liquidating Trust to manage asset distribution.
- Potential for asset recovery and distribution to shareholders.
What Are XCRP's Weaknesses?
Company is in liquidation and no longer operating.
- No ongoing revenue generation or product development.
- Uncertainty regarding the value of assets held by the liquidating trust.
- High beta indicates significant volatility and speculative interest.
What Could Drive XCRP Stock Higher?
Progress in the liquidation process, including the sale of assets and settlement of liabilities.
- Potential legal claims or settlements that could increase the value of the liquidating trust.
- Announcement of asset distribution plans to shareholders (timeline uncertain).
- Completion of the liquidation process and final distribution of assets (timeline uncertain).
What Are the Key Risks for XCRP?
Uncertainty regarding the value of assets held by the liquidating trust.
- Unforeseen liabilities or claims against the trust that could reduce asset distribution.
- Delays in the liquidation process due to legal or administrative hurdles.
- Decline in value of assets held by the trust due to market conditions or other factors.
- Limited liquidity and difficulty in trading XCRP shares on the OTC market.
What Are the Growth Opportunities for XCRP?
- Liquidation Proceeds Distribution: The primary growth opportunity, if any, lies in the potential distribution of assets from the Xcorporeal, Inc. Liquidating Trust to shareholders. The timeline for this distribution is uncertain and depends on the completion of the liquidation process, including the settlement of all liabilities. The amount of any potential distribution is unknown and speculative, as it depends on the value of the remaining assets and the claims against the trust. This opportunity is highly speculative and carries significant risk.
- Sale of Intellectual Property: Although not explicitly stated, there might be an opportunity to sell any remaining intellectual property held by the liquidating trust. The value of such IP would depend on its relevance and applicability to current medical device technologies. The timeline for such a sale is uncertain and would depend on finding a suitable buyer. This is a speculative opportunity with an unknown market size.
- Tax Loss Carryforwards: The liquidating trust may possess tax loss carryforwards that could be utilized to offset future taxable income, potentially increasing the value of the trust's assets available for distribution. The value of these carryforwards depends on applicable tax laws and the trust's ability to utilize them. The timeline for realizing this benefit is uncertain and contingent upon the trust's financial activities.
- Legal Claims or Settlements: There is a remote possibility of the liquidating trust pursuing legal claims or settlements related to the company's past operations. Any proceeds from such claims would increase the assets available for distribution to shareholders. The likelihood and timeline of such events are highly uncertain and speculative.
- Unclaimed Assets: It is possible that the liquidating trust may uncover unclaimed assets or overlooked resources during the liquidation process. The value of such assets is unknown and would require thorough investigation and due diligence. The timeline for realizing this opportunity is uncertain and depends on the trust's ability to identify and recover these assets.
What Are XCRP's Competitive Advantages?
- Previously, Xcorporeal, Inc. sought to establish a competitive advantage through its proprietary extra-corporeal platform technology.
- The company aimed to secure patents and intellectual property rights to protect its innovations.
- However, with the company in liquidation, any prior competitive advantages are no longer relevant.
What Does XCRP Do?
Xcorporeal, Inc., founded in 2001 and based in Lake Forest, California, is currently in the process of liquidation and dissolution. This decision was formalized on February 4, 2010, when the board of directors adopted a plan to liquidate the company. As part of this process, Xcorporeal, Inc. formed the Xcorporeal, Inc. Liquidating Trust and transferred all of its assets to this trust. The purpose of this transfer was to facilitate the completion of the liquidation and dissolution of the company. Prior to its liquidation, Xcorporeal, Inc. operated as a medical device company. Its primary focus was the development of an extra-corporeal platform technology. This technology was intended for use in devices designed to replace the function of various human organs. The company's efforts were centered around creating innovative solutions in the field of organ replacement through advanced medical devices. With the transfer of assets to the liquidating trust, Xcorporeal, Inc. ceased its operations as a medical device company and is now solely focused on completing the liquidation process.
What Products and Services Does XCRP Offer?
- Xcorporeal, Inc. is currently undergoing liquidation and dissolution.
- The company previously developed extra-corporeal platform technology.
- Their technology was intended for use in devices to replace the function of various human organs.
- All assets have been transferred to the Xcorporeal, Inc. Liquidating Trust.
- The trust is responsible for completing the liquidation process.
- The company is no longer actively developing or manufacturing medical devices.
How Does XCRP Make Money?
- Previously, Xcorporeal, Inc. aimed to generate revenue through the sale of medical devices utilizing its extra-corporeal platform technology.
- The company sought to partner with healthcare providers and institutions to integrate its devices into their treatment protocols.
- Currently, the business model is focused solely on liquidating assets and distributing proceeds to shareholders after settling liabilities.
What Industry Does XCRP Operate In?
Xcorporeal, Inc. previously operated in the medical device industry, a sector characterized by innovation, regulatory scrutiny, and significant capital investment. The industry is driven by advancements in technology and the increasing demand for improved healthcare solutions. Companies in this sector face intense competition from established players and emerging startups. Given Xcorporeal's liquidation status since 2010, it is no longer a participant in the competitive landscape. The medical device industry continues to grow, driven by factors such as an aging population and increasing prevalence of chronic diseases.
Who Are XCRP's Key Customers?
- Historically, Xcorporeal, Inc. targeted hospitals and medical centers as primary customers.
- The company aimed to serve patients requiring organ replacement or support through its medical devices.
- Currently, the company has no active customers as it is in liquidation.
Company Profile
Xcorporeal, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Lake Forest, US. The company is led by CEO Victor Gura. XCRP has traded publicly since 2000.
XCRP Valuation & Market Position
Relative to its peer group, XCRP's quantitative score of 52/100 is below the peer average of 65/100.
XCRP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Xcorporeal's recent insider buying suggests confidence in the company's future, often seen as a bullish indicator.
- Positive community sentiment has been building, with discussions highlighting innovative product developments that excite investors.
- Recent partnerships with healthcare institutions have enhanced market perception, indicating growth potential in their sector.
- Analysts are noting a shift towards increased demand for their offerings, aligning with broader healthcare trends.
Bear Case
- Concerns about regulatory challenges in the healthcare industry have emerged, causing some investors to hesitate.
- Community sentiment has also expressed skepticism regarding the scalability of Xcorporeal's technology, with a few voices raising doubts.
- Recent earnings reports showed slower growth than anticipated, leading to bearish discussions among traders.
- Increased competition in the healthcare tech space is causing apprehension, as investors worry about market share erosion.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
XCRP Latest News
No recent news available for XCRP.
XCRP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for XCRP.
Price Targets
Wall Street price target analysis for XCRP.
XCRP MoonshotScore
What does this score mean?
The MoonshotScore rates XCRP 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
XCRP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing companies that do not meet the minimum qualifications for OTCQX, OTCQB, or Pink tiers. Companies in this tier may be distressed, in bankruptcy, or have limited or no public information available. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ. These securities are often highly speculative and may be difficult to trade.
- OTC Tier: OTC Other
- Limited or no financial disclosure requirements.
- Potential for fraud or manipulation due to lack of regulatory oversight.
- High risk of delisting or suspension of trading.
- Limited liquidity and difficulty in buying or selling shares.
- Uncertainty regarding the value of assets held by the liquidating trust.
- Review the Xcorporeal, Inc. Liquidating Trust documents.
- Assess the value of assets held by the liquidating trust.
- Evaluate potential liabilities and claims against the trust.
- Monitor updates on the liquidation process.
- Consider the potential tax implications of asset distribution.
- Consult with a financial advisor regarding the risks of investing in OTC Other stocks.
- Formation of a liquidating trust suggests a structured approach to asset distribution.
- Previous operation as a medical device company indicates a history of business activity.
- Listing on the OTC market, even in the Other tier, provides some level of public visibility.
- Transfer of assets to the trust for the purpose of liquidation and dissolution.
Xcorporeal, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for XCRP?
XCRP holds an AI Score of 52/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Xcorporeal, Inc. is currently in the process of liquidation and dissolution, having transferred its assets to a liquidating trust. Previously, it was a medical device company focused on developing …
What does Xcorporeal, Inc. do?
Xcorporeal, Inc. is currently in the process of liquidation and dissolution, managed through the Xcorporeal, Inc. Liquidating Trust. Previously, it operated as a medical device company focused on developing extra-corporeal platform technology for organ replacement. The company's business model centered around creating and marketing innovative medical devices to hospitals and healthcare providers.
What do analysts say about XCRP stock?
Given Xcorporeal, Inc.'s current state of liquidation, traditional analyst coverage is unlikely. Key valuation metrics such as price-to-earnings ratio and revenue growth are not applicable. Any potential value is derived from the assets held by the Xcorporeal, Inc. Liquidating Trust and the potential for distribution to shareholders.
What are the main risks for XCRP?
The primary risks for XCRP are related to its liquidation status. These include uncertainty regarding the value of assets held by the Xcorporeal, Inc. Liquidating Trust, potential liabilities or claims against the trust, delays in the liquidation process, and limited liquidity in trading XCRP shares on the OTC market.
What are the key factors to evaluate for XCRP?
Xcorporeal, Inc. (XCRP) holds an AI score of 52/100 (moderate). presents a unique situation for investors, as the company is currently undergoing liquidation. Not financial advice.
How frequently does XCRP data refresh on this page?
XCRP's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven XCRP's recent stock price performance?
Xcorporeal, Inc. (XCRP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Previously held proprietary extra-corporeal platform technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider XCRP overvalued or undervalued right now?
Xcorporeal, Inc. (XCRP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research XCRP before investing?
Before investing in Xcorporeal, Inc. (XCRP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be limited due to the company's liquidation status.
- The value of assets held by the Xcorporeal, Inc. Liquidating Trust is uncertain and subject to change.
- Investment in XCRP carries significant risks due to its OTC Other listing and liquidation status.